ASN: Hypertension Most Common Cardiovascular Comorbidity Seen With Dialysis
By Lori Solomon HealthDay Reporter
WEDNESDAY, Oct. 30, 2024 -- Hypertension is the most common cardiovascular disease (CVD) comorbidity seen among dialysis patients globally, according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held from Oct. 23 to 27 in San Diego.
Belen Alejos, Ph.D., from Fresenius Medical Care in Bad Homburg, Germany, and colleagues analyzed CVD prevalence among 543,169 dialysis patients treated in 40 countries across six continents. The analysis included data from the first version of a global dialysis database (Apollo Dial DB; January 2018 to March 2021).
The researchers found that 79 percent of included patients reported at least one CVD condition, including most commonly hypertension (73.6 percent). There were some differences observed in the prevalence of CVD conditions by age and sex. For example, atherosclerotic heart disease affected 19.0 percent, with prevalence increasing with age (9.9 percent in ages 18 to 44 years to 24.1 percent in ages 75 years and older). Atherosclerotic heart disease was also more common in men (20.3 percent) than women (17.2 percent). A similar trend was seen for congestive heart failure, which affected 17.5 percent overall but increased with age. Other lower prevalence conditions, such as peripheral vascular disease (11.5 percent), cardiomyopathy (7.3 percent), and cardiac dysrhythmias (7.1 percent), were all more prevalent in older age groups and in men.
"Hypertension is the most common CVD comorbidity among dialysis patients globally, followed by atherosclerotic heart disease and congestive heart failure," the authors write. "Future analyses are needed to explore differences by world region, which could inform region-specific management strategies."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
GLP-1 Receptor Agonists May Improve Outcomes in Idiopathic Intracranial Hypertension
MONDAY, July 21, 2025 -- For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is associated with improved...
ENDO: Primary Aldosteronism Screening Recommended for All With Hypertension
FRIDAY, July 18, 2025 -- All individuals with hypertension should be screened for primary aldosteronism (PA), according to a clinical practice guideline issued by the Endocrine...
Delays in HTN Diagnosis Linked to Delays in Medication Prescribing
THURSDAY, July 17, 2025 -- Delays in diagnosis of hypertension are common and associated with delays in treatment initiation, according to a study published online July 14 in JAMA...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.